Variability in disease presentation, progression and treatment response has been a central
challenge in medicine. Although variability in host factors and genetics are important, it has …

Background Clostridioides difficile is a Gram-positive anaerobic bacterium, which causes
Clostridioides difficile infection (CDI). It has been recognised as a leading cause of …

Clostridioides difficile is the most common cause of nosocomial antibiotic-associated
diarrhea, and is responsible for a spectrum of diseases characterized by high levels of …

Fecal microbiota transplantation (FMT) is highly effective in preventing recurrent
Clostridioides difficile infection (rCDI). However, the mechanisms underpinning its clinical …

Clostridioides difficile (formerly Clostridium difficile) infection is a substantial health and
economic burden worldwide. Great strides have been made over the past several years in …

Aims: This study aimed to evaluate all-cause economic outcomes, healthcare resource
utilization (HRU), and costs in patients with Clostridioides difficile infection (CDI) and …

Background Intestinal microbiota restoration can be achieved by complementing a subject's
perturbed microbiota with that of a healthy donor. Recurrent Clostridioides difficile infection …

Clostridioides difficile, which causes life-threatening diarrheal disease, is considered an
urgent threat to healthcare setting worldwide. The current standards of care solely rely on …

Clostridioides difficile is a Gram-positive, spore-forming, anaerobic bacterium. The clinical
features of C. difficile infections (CDIs) can vary, ranging from the asymptomatic carriage and …

Background Fidaxomicin is a first-line treatment for Clostridioides difficile infections (CDIs).
Fidaxomicin resistance has rarely been reported in this urgent antimicrobial resistance …